NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: Bfflist AMO

Published 12 Nov 2026. 34-page investigative report on who is behind Bfflist AMO: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Bfflist AMO is a product-specific case, not a blanket yes/no. Across 74 Finnrick lab tests, the record is 55 pass / 19 fail for a 74% overall pass rate. Retatrutide is the strongest signal; Cagrilintide is the clearest avoid. Tirzepatide is mixed, and Semaglutide is thin and fail-leaning; borderline scores contract under stricter grading.

The larger risk is channel authentication. The historical Amo/BFF trail has continuity signals around Binh, Alan, AmoPeptide, AmoPure, Bfflist, BFFLink, and BFF Chem, but the live public shop is a newer bff-peptides.com site on different infrastructure. The Finnrick subject domain, bfflist.org, was parked and for sale at capture, while BFF Chem exposed active catalog records behind maintenance.

The COA page also needs a narrower read. It displays 43 certificate cards, but the implementation resolves to nine unique Janoshik verification leads, anonymized manufacturer fields, and no public received-vial-to-current-lot workflow. Storefront claims conflict on U.S. domestic lab versus Chinese sourcing, universal outside testing versus selected verification, and public COAs versus COAs on request.

Buyer recourse is thin: the live cart is crypto-only, policy pages were not found, and no legal entity, address, phone, owner, or batch-release authority is published. The full report separates historical reputation from the current storefront and shows where Retatrutide may be worth strict lot verification versus where the evidence points away.

Inside the full report:

  • Per-product Finnrick Appendix A and methodology-divergence charts for all 4 tested products
  • Domain-pivot timeline from AmoPeptide/AmoPure through BFF Chem and bff-peptides.com
  • EC21, UK Companies House, BFF Chem, Binh/Alan, and current-shop identity trail
  • COA and claims-diff analysis: Janoshik leads, anonymized manufacturer fields, and batch-lookup gaps
  • Payment, shipping, recourse, and SEO-confusion review, including crypto checkout and parked domains

Risk assessment

  • Channel-authenticity and copycat risk — high: bfflist.org is parked/for sale; bffpeptides.com, BFFLink, and bffamo are dead or unavailable; no official-channel list ties bff-peptides.com to Binh/Alan.
  • Irreversible-payment and buyer-recourse risk — high: Current BFF AMO checkout is crypto-only and publishes no refund policy, terms, address, phone, or legal counterparty.
  • Undisclosed legal-counterparty and ownership risk — high: BFF AMO publishes no entity; BFFCHEM Biotechnology LTD has no UK Companies House match; EC21 Amopeptide is self-reported.
  • COA and lot-traceability risk — high: BFF AMO shows 43 COA cards but only nine unique Janoshik URLs, anonymized manufacturer fields, and no current order-to-lot lookup.
  • Cagrilintide product-quality risk — high: Cagrilintide has 6 Finnrick tests with 1 pass / 5 fail and a 42.6% rating.
  • Tirzepatide product-quality risk — medium: Tirzepatide has 17 Finnrick tests with 11 pass / 6 fail and a 70.1% rating; historical stinging reports add lot-specific caution.
  • Semaglutide product-quality risk — medium: Semaglutide is thin and fail-leaning at 3 Finnrick tests with 1 pass / 2 fail and a 62.11% rating.